Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2017, Vol. 11 Issue (4) : 548-553    https://doi.org/10.1007/s11684-017-0597-5
RESEARCH ARTICLE
Impact of HBV replication in peripheral blood mononuclear cell on HBV intrauterine transmission
Xiaohong Shi1, Xuefei Wang1, Xixi Xu1, Yongliang Feng1, Shuzhen Li1, Shuying Feng2, Bo Wang2, Suping Wang1()
1. Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan 030001, China
2. Department of Obstetrics and Gynaecology, The Third People Hospital of Taiyuan City, Taiyuan 030001, China
 Download: PDF(111 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

This study determined the effect of hepatitis B virus (HBV) replication in peripheral blood mononuclear cell (PBMC) from HBsAg-positive mothers on HBV intrauterine transmission. A total of 150 HBsAg-positive mothers and their neonates were recruited in this study. Within 24 h after birth, HBV serological markers, serum HBV DNA, PBMC HBV relaxed circular DNA (rcDNA), and covalently closed circular DNA (cccDNA) were measured in the HBsAg-positive mothers and their neonates before passive-active immune prophylaxis. The relationship between HBV replication in PBMC and HBV intrauterine transmission was examined through Chi-square test and logistic regression. The rate of HBV intrauterine transmission was 8.00% (12/150) in the 150 neonates born to HBsAg-positive mothers. The positivities of PBMC HBV rcDNA and cccDNA in the HBsAg-positive mothers were 36.67% (55/150) and 10% (15/150), respectively. Maternal PBMC HBV cccDNA was a risk factor of HBV intrauterine transmission (OR= 6.003, 95% CI: 1.249–28.855). Maternal serum HBeAg was a risk factor of PBMC HBV rcDNA (OR= 3.896, 95% CI: 1.929–7.876) and PBMC HBV cccDNA (OR= 3.74, 95% CI: 1.186–11.793) in the HBsAg-positive mothers. Administration of hepatitis B immune globulin was a protective factor of PBMC HBV cccDNA (OR= 0.312, 95% CI: 0.102–0.954) during pregnancy. The positivity of PBMC HBV rcDNA was related to that of cccDNA in the HBsAg-positive mothers (c2=5.087, P= 0.024). This study suggests that PBMC is a reservoir of HBV and an extrahepatic site for virus replication and plays a critical role in HBV intrauterine transmission.

Keywords PBMC      HBV cccDNA      HBV rcDNA      HBV intrauterine transmission     
Corresponding Author(s): Suping Wang   
Just Accepted Date: 30 October 2017   Online First Date: 22 November 2017    Issue Date: 04 December 2017
 Cite this article:   
Xiaohong Shi,Xuefei Wang,Xixi Xu, et al. Impact of HBV replication in peripheral blood mononuclear cell on HBV intrauterine transmission[J]. Front. Med., 2017, 11(4): 548-553.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-017-0597-5
https://academic.hep.com.cn/fmd/EN/Y2017/V11/I4/548
Characteristics HBV intrauterine transmission P
Yes ( n) No ( n)
Age of mother (year) M (QR) 27 (5) 27 (7) 0.961 a
Gestational weeks M (QR) 39.5 (1.5) 40 (1) 0.528 a
Neonatal weight (g) M (QR) 3400 (600) 3000 (250) 0.009* ,a
Gender of neonate Male 4 68 0.368 b
Female 8 66
Mode of delivery Vaginal delivery 8 84 0.767
Caesarean section 4 54
Educational level of mother <High school 9 79 0.361
≥High School 3 59
History of hepatitis Negative 9 113 0.698
Positive 3 25
Family history of HBV infection Negative 8 98 0.748
Positive 4 40
Hepatitis B vaccine injection Negative 12 125 0.601
Positive 0 13
HBIG administration Negative 4 48 1.000
Positive 8 90
History of blood transfusion Negative 12 134 1.000
Positive 0 4
History of acupuncture Negative 12 128 1.000
Positive 0 10
History of dental treatment Negative 11 101 0.297
Positive 1 37
History of abortion or induced labor Negative 7 92 0.543
Positive 5 46
Medication use during pregnancy Negative 11 103 0.295
Medication use during pregnancy Positive 1 35
Threatened abortion Negative 10 126 0.310
Positive 2 12
Antepartum hemorrhage Negative 10 126 0.310
Positive 2 12
Maternal serum HBV DNA Negative 3 81 0.024* ,b
Positive 9 57
Maternal PBMC HBV rcDNA Negative 7 88 0.760
Positive 5 50
Maternal PBMC HBV cccDNA Negative 8 127 0.020*
Positive 4 11
Maternal HBeAg Negative 2 91 0.001*
Positive 10 47
Tab.1  Influencing factors of HBV intrauterine transmission
HBV intrauterine transmission OR (95% CI)
Yes ( n) No ( n)
rcDNA/cccDNA
− and − 6 87 1.0
+ or+ 6 51 1.344 (0.349−5.181)
− and+ 1 1 21.532 (0.891−520.227)
+ and − 2 40 0.564 (0.095−3.336)
+ and+ 3 10 3.586 (0.589−21.827)
rcDNA
7 88 1.0
+ 5 50 0.430 (0.082−2.238)
cccDNA
8 127 1.0
+ 4 11 6.003 (1.249−28.855)
Tab.2  Effect of maternal PBMC HBV infection and replication on HBV intrauterine transmission
β S.E. Wald c2 P OR (95% CI)
PBMC HBV rcDNA or cccDNA
HBeAg 1.374 0.358 14.745 <0.001 3.953 (1.96–7.973)
PBMC HBV rcDNA
HBeAg 1.360 0.359 14.334 <0.001 3.896 (1.929–7.876)
PBMC HBV cccDNA
HBeAg 1.319 0.586 5.070 <0.024 3.74 (1.186–11.793)
HBIG administration −1.165 0.570 4.168 0.041 0.312 (0.102–0.954)
Tab.3  Influencing factors of PBMC HBV infection and replication in HBsAg-positive mothers
1 Ott JJ, Stevens  GA, Groeger J ,  Wiersma ST . Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30(12): 2212–2219
https://doi.org/10.1016/j.vaccine.2011.12.116 pmid: 22273662
2 Trépo C, Chan  HL, Lok A . Hepatitis B virus infection. Lancet 2014; 384(9959): 2053–2063
https://doi.org/10.1016/S0140-6736(14)60220-8 pmid: 24954675
3 Cardoso AC, Carvalho-Filho  RJ, Stern C ,  Dipumpo A ,  Giuily N ,  Ripault MP ,  Asselah T ,  Boyer N ,  Lada O, Castelnau  C, Martinot-Peignoux M, Valla DC ,  Bedossa P ,  Marcellin P . Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 2012; 32(4): 612–621
https://doi.org/10.1111/j.1478-3231.2011.02660.x pmid: 22103765
4 Başar O, Yimaz  B, Ekiz F ,  Giniş Z ,  Altinbaş A ,  Aktaş B ,  Tuna Y, Çoban  S, Delibaş N ,  Yüksel O . Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013; 37(2): 152–158
https://doi.org/10.1016/j.clinre.2012.07.003 pmid: 23391746
5 Xu YY, Liu  HH, Zhong YW ,  Liu C, Wang  Y, Jia LL ,  Qiao F, Li  XX, Zhang CF ,  Li SL, Li  P, Song HB ,  Li Q. Peripheral blood mononuclear cell traffic plays a crucial role in mother-to-infant transmission of hepatitis B virus. Int J Biol Sci 2015; 11(3): 266–273
https://doi.org/10.7150/ijbs.10813 pmid: 25678845
6 Bai GQ, Li  SH, Yue YF ,  Shi L. The study on role of peripheral blood mononuclear cell in HBV intrauterine infection. Arch Gynecol Obstet 2011; 283(2): 317–321
https://doi.org/10.1007/s00404-010-1366-8 pmid: 20107823
7 Cabrerizo M, Bartolomé  J, Caramelo C ,  Barril G ,  Carreño V . Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32(1): 116–123
https://doi.org/10.1053/jhep.2000.8541 pmid: 10869298
8 Shi XH, Wang  SP, Li SZ ,  Xie LJ, Feng  LP, Shuang JY . Study on replication status of HBsAg positive pregnant women and newborns. Chin J Publ Health (Zhongguo Gong Gong Wei Sheng) 2004; 20(5): 513–514 (in Chinese)
9 Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015; 64(12): 1972–1984
https://doi.org/10.1136/gutjnl-2015-309809 pmid: 26048673
10 Tong S, Revill  P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016; 64(1 Suppl): S4–S16
https://doi.org/10.1016/j.jhep.2016.01.027 pmid: 27084035
11 Cai D, Wang  X, Yan R ,  Mao R, Liu  Y, Ji C ,  Cuconati A ,  Guo H. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res 2016; 132: 26–37
https://doi.org/10.1016/j.antiviral.2016.05.005 pmid: 27185623
12 Zou H, Chen  Y, Duan Z ,  Zhang H ,  Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19(2): e18–e25
https://doi.org/10.1111/j.1365-2893.2011.01492.x pmid: 22239517
13 Li XM, Shi  MF, Yang YB ,  Shi ZJ, Hou  HY, Shen HM ,  Teng BQ . Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004; 10(21): 3215–3217
https://doi.org/10.3748/wjg.v10.i21.3215 pmid: 15457579
14 Bissig KD, Wieland  SF, Tran P ,  Isogawa M ,  Le TT, Chisari  FV, Verma IM . Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120(3): 924–930
https://doi.org/10.1172/JCI40094 pmid: 20179355
15 Coffin CS, Mulrooney-Cousins  PM, Peters MG ,  van Marle G ,  Roberts JP ,  Michalak TI ,  Terrault NA . Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat 2011; 18(6): 415–423
https://doi.org/10.1111/j.1365-2893.2010.01321.x pmid: 20626626
16 Brind A, Jiang  J, Samuel D ,  Gigou M ,  Feray C ,  Bréchot C ,  Kremsdorf D . Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997; 26(2): 228–235
https://doi.org/10.1016/S0168-8278(97)80035-9 pmid: 9059940
17 Stoll-Becker S, Repp  R, Glebe D ,  Schaefer S ,  Kreuder J ,  Kann M, Lampert  F, Gerlich WH . Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol 1997; 71(7): 5399–5407
pmid: 9188611
18 Zhang YL, Xu  D, Wu XX ,  Wu J, Shao  XY, Chen H ,  Zhang Q . HBVcccDNA of patients with hepatitis B in the serum, PBMC and liver tissue distribution. Chin J Exp Clin Virol (Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi) 2008; 22(5): 342–344 (in Chinese)
pmid: 19469169
19 Shao Q, Zhao  X, Yao Li MD . Role of peripheral blood mononuclear cell transportation from mother to baby in HBV intrauterine infection. Arch Gynecol Obstet 2013; 288(6): 1257–1261
https://doi.org/10.1007/s00404-013-2893-x pmid: 23708388
20 Guo Z, Shi  XH, Feng YL ,  Wang B, Feng  LP, Wang SP ,  Zhang YW . Risk factors of HBV intrauterine transmission among HBsAg-positive pregnant women. J Viral Hepat 2013; 20(5): 317–321
https://doi.org/10.1111/jvh.12032 pmid: 23565613
21 Xu DZ, Yan  YP, Choi BCK ,  Xu JQ, Men  K, Zhang JX ,  Liu ZH, Wang  FS. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002; 67(1): 20–26
https://doi.org/10.1002/jmv.2187 pmid: 11920813
22 Yu MM, Gu  XJ, Xia Y ,  Wang GJ ,  Kan NY, Jiang  HX, Wu KH ,  Ji Y, Ju  LL. Relationship between HBV cccDNA expression in the human ovary and vertical transmission of HBV. Epidemiol Infect 2012; 140(8): 1454–1460
https://doi.org/10.1017/S0950268811002068 pmid: 22000033
23 Wang XJ, Wang  SP, Li TG ,  Feng YL . The status of HBV infection in peripheral blood mononuclear cells from 114 HBsAg-positive mothers and their newborns. J Guangdong Med Coll ( Guangdong Yi Xue Yuan Xue Bao) 2006; 24(2): 131–133 (in Chinese)
24 Wei JN, Wang  SP, Shuang JY . Study on the relationship between fetomaternal cellular traffic and hepatitis B virus intrauterine infection. Chin J Epidemiol (Zhonghua Liu Xing Bing Xue Za Zhi)  2005; 26(4): 240–244 (in Chinese)
pmid: 15941526
25 Zhu Q, Yu  G, Yu H ,  Lu Q, Gu  X, Dong Z ,  Zhang X . A randomized control trial on interruption of HBV transmission in uterus. Chin Med J (Engl) 2003; 116(5): 685–687
pmid: 12875680
26 Yuan J, Lin  J, Xu A ,  Li H, Hu  B, Chen J ,  Yao J, Dong  H, Jiang M . Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat 2006; 13(9): 597–604
https://doi.org/10.1111/j.1365-2893.2006.00738.x pmid: 16907846
27 Li F, Cheng  L, Murphy CM ,  Reszka-Blanco NJ ,  Wu Y, Chi  L, Hu J ,  Su L. Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Sci Rep 2016; 6(1): 36483
https://doi.org/10.1038/srep36483 pmid: 27819342
28 Kennedy EM, Kornepati  AV, Cullen BR . Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Antiviral Res 2015; 123: 188–192
https://doi.org/10.1016/j.antiviral.2015.10.004 pmid: 26476375
29 Dong C, Qu  L, Wang H ,  Wei L, Dong  Y, Xiong S . Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 2015; 118: 110–117
https://doi.org/10.1016/j.antiviral.2015.03.015 pmid: 25843425
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed